4 unknown, 3 completed, 3 recruiting, 1 active not recruiting. 7 Phase 2, 6 Phase 1, 2 Phase 3, 1 Not applicable.
Follow Azacitidine Injection: new trials by email Literature Review of Azacitidine Injection trials Research Report on Azacitidine Injection
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Lisaftoclax (APG-2575) Combined With Azacytidine (AZA) in the Treatment of Patients With Higher-risk Myelodysplastic Syndrome (GLORA-4). Lisaftoclax (APG-2575), Azacitidine Injection, Placebo - Higher-risk Myelodysplastic Syndrome | Phase 3 | Recruiting | Ascentage Pharma Group Inc. | 490 | 2025-01-22 | 2026-10-13 |
| Acute Myeloid Leukemia Treated With With NETrin Abs in Combination With [AZACITIDINE + VENETOCLAX] NP137, Azacitidine Injection, Venetoclax - Acute Myeloid Leukemia Refractory | Phase 1 / Phase 2 | Terminated | Centre Leon Berard | 1 | 2024-09-11 | 2025-02-20 |
| A Pivotal Study of APG-2575 (Lisaftoclax) Combined With Azacitidine in the Treatment of Acute Myeloid Leukemia APG-2575(Lisaftoclax ), Placebo, Azacitidine Injection - Acute Myeloid Leukemia | Phase 3 | Recruiting | Ascentage Pharma Group Inc. | 486 | 2024-06-11 | 2025-11-25 |
| CD19CD22 CAR-T Therapy in Patients With High-Risk B Acute Lymphoblastic Leukemia (B-ALL). Azacitidine Injection, Venetoclax, CD19CD22 CAR-T - B Acute Lymphoblastic Leukemia, Ph-Negative ALL | Phase 2 | Unknown | The First Affiliated Hospital of Soochow University | 20 | 2024-04-20 | 2024-04-22 |
| A Novel Conditioning Regimen for Myelodysplastic Syndrome With Moderate High IPSS-M Score Azacitidine Injection - Myelodysplastic Syndromes | Not applicable | Unknown | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 40 | 2024-03-01 | 2024-02-28 |
| Safety and Efficacy of Avapritinib in Relapsed or Refractory Pediatric CBF-AML With KIT Mutation Avapritinib, Azacitidine Injection, Decitabine Injection - AML, Childhood, Relapse/Recurrence | Phase 2 | Recruiting | Children's Hospital of Soochow University | 50 | 2024-03-01 | 2024-08-22 |
| Azacytidine During Anti-tuberculosis Therapy Azacitidine Injection - Tuberculosis, Pulmonary | Phase 1 / Phase 2 | Withdrawn | Andrew Dinardo | 2022-10-01 | 2023-02-08 | |
| A Umbrella Study in R/R PTCL Guided by Molecular Subtypes Azacitidine Injection, Dasatinib, Linperlisib - Peripheral T Cell Lymphoma | Phase 1 / Phase 2 | Unknown | Ruijin Hospital | 116 | 2022-09-30 | 2022-11-09 |
| Low-dose Venetoclax and Azacitidine as Front-line Therapy in Newly Diagnosed AML Venetoclax 100 MG, Itraconazole capsule, Azacitidine Injection - AML | Phase 2 | Completed | Hospital Universitario Dr. Jose E. Gonzalez | 15 | 2021-07-26 | 2023-01-25 |
| Relatlimab With Nivolumab and 5-Azacytidine for the Treatment of AML Azacitidine Injection, Nivolumab, Relatlimab - Acute Myeloid Leukemia | Phase 2 | Unknown | Ludwig-Maximilians - University of Munich | 30 | 2021-05-05 | 2022-11-08 |
| Pharmacokinetics, Tolerability and Safety of NEX-18a NEX-18a injection, Azacitidine Injection - Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) | Phase 1 | Completed | Nanexa AB | 2 | 2021-04-27 | 2023-10-17 |
| Vorinostat Dose-escalation After Allogeneic Hematopoietic Cell Transplantation Vorinostat, Azacitidine Injection - Acute Myeloid Leukemia, Myelodysplastic Syndromes | Phase 1 | Active not recruiting | Johns Hopkins All Children's Hospital | 15 | 2019-05-01 | 2026-07-15 |
| Azacitidine Plus Phenylbutyrate in Treating Patients With Advanced or Metastatic Solid Tumors That Have Not Responded to Previous Treatment Azacitidine Injection, sodium phenylbutyrate - Lymphoma, Small Intestine Cancer | Phase 1 | Completed | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 34 | 2000-03-01 | 2019-01-11 |
Leukemia, Myeloid, Acute (7) · Myelodysplastic Syndromes (3) · Burkitt Lymphoma (2) · Recurrence (2) · Hodgkin Disease (1) · Immunoblastic Lymphadenopathy (1) · Intraocular Lymphoma (1) · Leukemia, Biphenotypic, Acute (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Leukemia, Myelomonocytic, Chronic (1) · Leukemia, Myelomonocytic, Juvenile (1) · Lymphoma (1) · Lymphoma, B-Cell, Marginal Zone (1) · Lymphoma, Follicular (1) · Lymphoma, Large B-Cell, Diffuse (1)
Ascentage Pharma Group Inc. (2) · Andrew Dinardo (1) · Centre Leon Berard (1) · Children's Hospital of Soochow University (1) · Hospital Universitario Dr. Jose E. Gonzalez (1) · Johns Hopkins All Children's Hospital (1) · Ludwig-Maximilians - University of Munich (1) · Nanexa AB (1) · Ruijin Hospital (1) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1) · The First Affiliated Hospital of Soochow University (1) · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (1)
China (5) · United States (4) · France (2) · Germany (2) · Sweden (2) · Australia (1) · Belgium (1) · Bulgaria (1) · Canada (1) · Czechia (1) · Finland (1) · Greece (1) · Hungary (1) · Italy (1) · Mexico (1)
Andrew DiNardo (1) · Cassandra Josephson, MD (1) · David Gomez-Almaguer (1) · Guillermo Garcia-Manero, M.D. (1) · Jianxiang Wang, M.D. (1) · Jie Jin, M.D. (1) · Linghui Xia (1) · Marion Subklewe, MD (1) · Michael A. Carducci, MD (1) · Shaoyan Hu, MD, PhD (1) · Weili Zhao (1) · Xiaojun Huang, M.D., Ph.D. (1)
P30CA006973 (1), P50CA058236 (1), R01CA075525 (1), U01CA070095 (1)